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Background: Notch4 is a member of the Notch family of receptors that is primarily expressed in the vascular
endothelial cells. Genetic deletion of Notch4 does not result in an overt phenotype in mice, thus the function of
Notch4 remains poorly understood.
Methods: We examined the requirement for Notch4 in the development of breast cancer vasculature. Orthotopic
transplantation of mouse mammary tumor cells wild type for Notch4 into Notch4 deficient hosts enabled us to
delineate the contribution of host Notch4 independent of its function in the tumor cell compartment.
Results: Here, we show that Notch4 expression is required for tumor onset and early tumor perfusion in a mouse
model of breast cancer. We found that Notch4 expression is upregulated in mouse and human mammary tumor
vasculature. Moreover, host Notch4 deficiency delayed the onset of MMTV-PyMT tumors, wild type for Notch4, after
transplantation. Vessel perfusion was decreased in tumors established in Notch4-deficient hosts. Unlike in inhibition
of Notch1 or Dll4, vessel density and branching in tumors developed in Notch4-deficient mice were unchanged.
However, final tumor size was similar between tumors grown in wild type and Notch4 null hosts.
Conclusion: Our results suggest a novel role for Notch4 in the establishment of tumor colonies and vessel
perfusion of transplanted mammary tumors.
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Notch signaling underlies an evolutionarily conserved
mechanism that regulates a wide range of cellular pro-
cesses via direct cell-cell communication. In mammals,
there are five Notch ligands (Jagged1, Jagged2, Delta-like
1/Dll1, Dll3, and Dll4) and four Notch receptors
(Notch1-4). The interaction between the Notch ligand
and its receptor triggers two proteolytic cleavages that
release the Notch intracellular domain into the nucleus.
There, the Notch intracellular domain forms complexes
with members of the CSL transcription factor family
(CBF1/RBP-Jκ/Suppressor of Hairless/LAG-1), leading
to the expression of downstream transcription factors
(reviewed in [1]).
Among the four Notch receptors, Notch1 and Notch4
are expressed in the vascular endothelium, with Notch4
expression being more restricted to endothelial cells* Correspondence: rong.wang@ucsfmedctr.org
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reproduction in any medium, provided the or(ECs) [2]. Mice homozygous for a null allele of Notch1
develop vascular abnormalities and die in utero shortly
after primitive vascular plexus formation [3,4]. Homozy-
gous Notch4 null mice develop normally and are viable
and fertile. However, the combination of homozygous
loss of Notch1 and Notch4 results in a more pronounced
vascular phenotype than the Notch1 null homozygous
alone [3,4]. Even though this finding suggests that lack
of Notch4 can exacerbate the effect of Notch1 defi-
ciency, the unique role for Notch4 in vascular develop-
ment is unknown. In adult mice, genetic deletion of
Notch4 does not lead to any detectable abnormalities,
other than a slightly elevated systolic blood pressure
after experimental induction of hindlimb ischemia [3,5].
Angiogenesis, the formation of new vessels from pre-
existing ones, plays a key role in cancer and other
pathological conditions. Solid tumors depend on the de-
velopment of blood vessels to provide oxygen and nutri-
ents to support their growth [6]. Interfering with
Notch1 signaling dramatically affects angiogenesis in
the developing and pathological vasculatures (reviewedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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sprouting and “non-productive” angiogenesis, which re-
sults in decreased vessel perfusion and inhibition of tumor
growth [9,10]. Additionally, selective blocking of Notch1
with antibodies inhibits tumor growth by a mechanism
consistent with that of Dll4 inhibition, namely by promot-
ing abnormal growth of vessel sprouts that do not perfuse
tissues [11]. Thus while the importance of the Dll4-Notch1
signaling axis in tumor angiogenesis is well documented,
whether Notch4, primarily expressed in the endothelium,
is required for angiogenesis, vascular perfusion, and tumor
progression is unknown.
To unravel the role of Notch4 in tumor angiogenesis,
we chose breast cancer as a solid tumor model. Since
Notch4 is predominantly expressed in the vascular endo-
thelium in mice [2], we therefore used orthotopic trans-
plantation of mouse mammary carcinoma cells wild type
for Notch4 into syngeneic Notch4-deficient hosts to test
the importance of Notch4 in tumor angiogenesis.
Methods
Animals and human samples
C57BL/6J wild type mice were purchased from Jackson
Laboratory. MMTV-PyMT transgenic mice in C57 back-
ground were provided by Dr. Zena Werb’s lab at the
University of California, San Francisco (UCSF). All
strains were bred and maintained in a C57BL/6J back-
ground. We crossed wild type mice to Notch4−/− mice to
obtain Notch4+/− mice, which were then intercrossed to
generate Notch4−/− and Notch4+/+ controls. Mice were
kept in a pathogen-barrier facility from the time of
breeding to euthanasia.
Human breast cancer samples (paraffin-embedded tis-
sue blocks) were obtained from the UCSF Breast Cancer
SPORE tissue core, which collected samples in compli-
ance with a protocol approved by the UCSF Committee
on Human Research. Patient consent was obtained using
the standard surgical consent form, in combination with
the brochure, Donating Tissue for Medical Research.
The research involved collection of left-over specimens
and, as such, involved no more than minimal risk to the
subjects. Our use of these tissues was also approved by
the UCSF Committee on Human Research.
Immunostaining
Paraffin tissue sections of human samples were processed
using standard methods. Mouse tissue samples were fixed
in 4% formaldehyde in phosphate-buffered saline (PBS),
embedded in OCT (Tissue Tek), frozen, and cryosectioned.
Immunostaining was performed using rabbit anti-Notch4
(Upstate, diluted 1/1000) and rat anti-mouse CD31 (MEC
13.3, Pharmingen, diluted 1/500) as previously described
[12,13]. Secondary antibodies were Cy3-conjugated donkey
anti-rabbit (diluted 1/1000) and alexa-488 donkey anti-rat(diluted 1/1000), both from Jackson ImmunoResearch. In
experiments with mouse tissue tumors, sections were col-
lected from three different regions of each tumor and
quantification was performed from three different fields
per section. When tumors were not detected by naked eye,
the whole mammary fat pad was preserved for sectioning
and microscopical analysis.
Animal procedures
Animal experiments were performed in compliance with
the guidelines of UCSF Institutional Animal Care and
Use Committee (IACUC), who approved this study
under protocol #AN085404 and AN075264. We rou-
tinely monitored our mice targeted for tumorigenesis be-
fore and during tumor formation. Mice that displayed
any of the following signs were euthanized: loss of 15%
of their initial body weight, tumor size of 2 cm in the
largest dimension, or decline in activity.
Isolation of primary tumor cells and orthotopic
transplantation
Primary tumor epithelial cells were isolated from mam-
mary carcinomas that developed in MMTV-PyMT mice as
previously described [14]. Briefly, tumors were dissected
from 4–5 month old females, minced with razor blades
and collagenase-digested (Sigma Blend L 0.5 mg/ml in
RPMI 1640, supplemented with 10 mM Hepes and 5% fetal
bovine serum) for 1 hour at 37°C with continuous agita-
tion. The resultant mammary epithelial “organoids” were
washed in Hank’s medium with calcium and magnesium
(with 5% fetal bovine serum), separated from single cells
and blood through differential centrifugation, trypsinized
for 20 minutes and treated with DNaseI to obtain single
cell suspensions. These were immediately frozen at 5 × 106
cells/vial, and preserved in liquid nitrogen for later use.
Each cell aliquot was then thawed and used for transplants
in paired sets of Notch4−/− and control animals. Cells were
washed and resuspended in ice-cold PBS. Mice were anes-
thetized using isoflurane and a ventral incision was made
to expose the fourth inguinal mammary glands. Approxi-
mately 106 cells (in a 10 μl volume) were injected into syn-
geneic C57BL/6J wild type or Notch4−/− female mice at
3 weeks of age. Tumor development was monitored every
other day by palpation.
Vessel perfusion studies
Mice were anesthetized with isoflurane and injected in
the tail vein with a combination of 60 μg of biotinylated
Lycopersicon esculentum lectin (Vector Laboratories,
Burlingame, CA) and 60 μg of Cy3-streptavidin (Jackson
ImmunoResearch). Mice were further anesthetized with
ketamine/xylazine. After 5 minutes, the chest was
opened and the vasculature was perfused with PBS
through the left ventricle for 5 minutes, followed by 4%
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Real-time PCR
Total RNA was isolated from normal mammary inguinal
fat pads and from transplanted tumors using Trizol
(Invitrogen), following the manufacturer’s instructions.
RNA was further purified from contaminant genomic DNA
with DNase I treatment and RNeasy columns (Qiagen), fol-
lowing the manufacturer’s instructions. RNA was retro-
transcribed using SuperscriptIII (Invitrogen) and SYBR
Green-based real-time-PCR was used to analyze gene ex-
pression. Normalized fold change in gene expression in
tumor relative to normal gland was calculated according to
Pffafl [15], using Tie2,VE-cadherin, and CD31 as reference









Immunoprecipitation and western blotting
Immunoprecipitation of Notch4 from lysates of normal
mammary gland at pubertal stage followed by Western
blotting analysis was performed as previously described
[16] using a polyclonal rabbit anti-Notch4 antibody
(Upstate).
Statistical analysis
Vessel density and perfusion analysis was performed
as previously described [13]. Data are expressed as
mean + standard error of the mean (s.e.m). P-values
were calculated using a two-tailed t test except for tumor
onset analysis where Fisher’s exact test was applied. Values
of p≤0.05 were considered statistically significant.
Results
Notch4 expression is upregulated in the vasculature of
mouse and human mammary tumors
To test the hypothesis that Notch4 is involved in patho-
logical angiogenesis, we used mammary tumors as a
model. We first assessed whether an orthotopic tumor
model derived from the MMTV-PyMT (polyoma middle
T antigen driven by the mouse mammary tumor virus
LTR) transgenic mouse line is a valid experimental tool
to study the functional relevance of Notch4 in breast
cancer development and angiogenesis. PyMT is a potent
oncogene that activates oncogenic signaling pathways
frequently upregulated in human breast cancer [17]. Inthe MMTV-PyMT mouse, PyMT is under the control of
the MMTV LTR, targeting PyMT expression to the
mammary epithelium. The expression of this transgene
leads to tumor development that closely mimics several
morphological stages of human breast tumor initiation
and progression [18]. We started by comparing Notch4
expression between MMTV-PyMT tumors generated by
orthotopic transplantation and normal mammary glands.
To this end, we injected primary tumor cells (at the carcin-
oma stage) derived from MMTV-PyMT mice into the in-
guinal mammary fat pads of wild type syngeneic female
mice. Three weeks after transplantation, we performed co-
immunostaining for Notch4 and CD31, to identify endothe-
lial cells. Mammary glands from non-injected, wildtype
mice were stained in parallel as controls (Figure 1a, i-vi).
The anatomical location of the vasculature relative to the
normal mammary structures has been reported in mice.
The two structures are closely associated [19,20]. We found
that Notch4 expression in the tumor was mostly restricted
to the endothelium (Figure 1a, vii-xii and Figure 1b i-iii), an
expression pattern that resembles that in the normal tissues
(Figure 1a, i-vi). More importantly, we discovered that
Notch4 immuno-reactivity was increased in vessels of the
tumor (Figure 1a, vii-xii) relative to that in normal mouse
mammary glands (Figure 1a, i-vi). A few cells that did not
mark for CD31, but were positive for Notch4 (likely mye-
loid cells, [21]), were also detected both in the normal
mammary gland (Figure 1a, i-vi) and infiltrating the solid
tumor epithelium (Figure 1a, x-xii).
To corroborate our immunostaining data, Notch4
mRNA expression was measured by quantitative RT-PCR
in four independent sets of normal mouse mammary
glands and tumors derived from MMTV-PyMT cells
transplanted into contra-lateral mammary glands. Since
vessel density is known to be increased in the mammary
glands of tumor-bearing mice [22], Notch4 mRNA levels
were expressed relative to three endothelium-specific
genes: Tie2,VE-cad, and CD31. We found that the levels of
Notch4 mRNA were increased in the mouse mammary
tumor tissue relative to normal glands (Figure 1c).
Next, we examined human biopsy samples (n=6) from
infiltrating ductal carcinoma, which were immunostained
with an antibody against Notch4. We found increased
Notch4 expression specifically in the tumor vasculature
(Figure 1d, ii) relative to blood vessels in the adjacent nor-
mal tissue (Figure 1d, i). This result indicates that, consist-
ent with the finding in mice, up-regulation of vascular
Notch4 also occurs in human breast tumorigenesis and
suggests that host Notch4 may play a role in breast tumor
angiogenesis.
Taken together, our results show that Notch4 expression
is upregulated in the tumor vasculature in both murine and
human mammary tumors, suggesting a possible role for
this receptor in breast cancer formation and angiogenesis.
Figure 1 (See legend on next page.)
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Figure 1 Notch4 expression is upregulated in the vasculature of mouse and human mammary tumors. (a) Notch4/CD31 immunostaining
reveals an increase of Notch4 expression in the vasculature of mouse orthotopic MMTV-PyMT mammary tumors (vii-xii) compared to age and
stage matched (virgin 8 weeks old) normal mouse mammary glands (i-vi). In panels vii-viii arrows indicate Notch4 low-expressing vessels;
arrowheads indicate Notch4 positive vessels. Panels i to iii show low expression levels of Notch4 and CD31 in the vessels of normal mammary
gland. Panels iv to vi show a detail of the staining of Notch4 and CD31 in the vessels of normal mammary gland. Panels vii-xii show Notch4 and
CD31 staining in tumors without adjacent normal tissues in these images. Panels vii and ix show higher expression of Notch4 in vessels of the
tumors than those in the normal gland (as compared to panels i and iii). Panels x (Notch4 staining), xi (CD31 staining) and xii (merged) show
higher magnification of tumor vessels with Notch4 expression. (b) Notch4 staining in the tumor is mainly restricted to the vasculature.
Orthotropic MMTV-PyMT mammary tumors at 3 weeks post transplant were immunostained for (i) Notch4, and (ii) CD31. Panel iii shows the
merge of Notch4 and CD31. (c) Notch4 mRNA expression is increased in orthotopic tumors derived from transplanted MMTV-PyMT cells
compared to normal mammary tissue as measured by quantitative RT-PCR. Data is represented as fold change of Notch4 expression in tumor
over normal mammary glands, normalized to the expression of Tie2, VE-cadherin and CD31. Samples were analyzed in duplicate and error bars
represent standard error of mean (s.e.m). (d) Notch4 immunostaining (brown stain) is increased in the vasculature of human infiltrating ductal
carcinoma tissue (ii) compared to adjacent normal tissue (i). Arrows indicate Notch4 staining in the endothelium.
Figure 2 Vessel density is comparable in Notch4-deficient and
wild type mouse mammary glands. (a) CD31 immunostaining
(green) pattern is similar in wild type (i) and Notch4−/− (ii) mouse
mammary glands. (b) Vessel density (represented as branch points/
20X field in intact inguinal mammary fat pads) is similar in wild type
and Notch4−/− mice. Bars represent average values and error bars
represent s.e.m.
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along with poor vessel perfusion
To study the function of Notch4 during angiogenesis in
mammary tumors, we took advantage of the orthotopic
tumor model described above. This model lets us test
host Notch4 effects independently of tumor Notch4 ef-
fects, because tumor cells from a Notch4+/+ mouse can
be transplanted into a syngeneic Notch4−/− mouse. We
verified that the Notch4 protein was absent in Notch4−/−
mice by performing immunoprecipitation and western
blot analysis on mammary tissue lysates from wild type,
Notch4+/−, and Notch4−/− mice. As expected, we ob-
served deletion of Notch4 at the protein level in mam-
mary glands from Notch4−/− mice (Additional file 1:
Figure S1). A previous study showed that mammary
glands isolated from virgin, pregnant, and lactating
Notch4−/− female mice display no detectable morpho-
logical or histological defects, but the mammary gland
vasculature in these mice was not characterized [3]. To
examine a possible role for Notch4 in mammary vascu-
lar morphogenesis, we compared the vessel density in
the mammary gland between wild type and Notch4−/−
mice at 3 weeks of age, same age at which mice were
transplanted with tumor cells. Vessel density was ana-
lyzed by immunostaining for CD31 and counting the
number of branch points (the point at which one vessel
segment splits into two or more vessel segments). We
found that vessel density in Notch4−/− mammary glands
was unaffected by the mutation (Figure 2a, i-ii and 2b).
Our results, together with those from previously pub-
lished studies, suggest that the mammary vasculature de-
velops normally in the absence of Notch4.
We next compared the onset of palpable tumors in wild
type and Notch4−/− mammary glands upon orthotopic in-
jection of syngeneic primary MMTV-PyMT tumor cells
wild type for Notch4. We designate the appearance of
palpable tumors after injection of single cells dissociated
from carcinoma tissues as tumor onset (hereafter referred
to as such). Tumor onset in orthotopic transplants cannotcompletely mimic natural tumor progression, but it does
allow us to determine the contributions from the tumor
vs. host microenvironment and to explore the tumor-host
interactions that are critical in tumor growth and progres-
sion. We scored the transplanted mice for incidence of
tumor onset at different times after transplantation. We
found that tumor onset was significantly delayed in
Notch4−/− hosts compared to wild type controls. One
week after transplantation, tumor incidence was 27% in
wild type hosts, but only 7% in Notch4−/− hosts, and two
weeks after transplantation, tumor incidence was still sig-
nificantly reduced in the Notch4−/− hosts (Figure 3). Three
Figure 3 Host Notch4 deficiency delays onset of tumors derived from orthotopic transplantation of MMTV-PyMT cells. Incidence of
palpable tumors in wild type and Notch4−/− mice at 1, 2 and 3 weeks post orthotopic transplantation of MMTV-PyMT tumor cells. Tumor onset is
significantly delayed in Notch4−/− mice at the early time points.
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tumor whereas 86% of Notch4−/− hosts presented tumors,
although this difference was not statistically significant
(Figure 3). From the very few tumors that were detected at
one week after transplantation, we found that the average
tumor mass was 0.018±0.004 (s.d.) grams in five tumors
developed in wild type hosts. However, the tumors devel-
oped in Notch4−/− hosts were too small to be measured.
Therefore, our results reveal that host Notch4 plays a ne-
cessary role in tumor onset.
Given that Notch4 is predominantly expressed in the
normal endothelium and upregulated in the tumor vascu-
lature, we examined blood vessels of tumors transplanted
into wild type and Notch4−/− mice. We performed this ana-
lysis by one week after transplantation, when there is a
large difference in tumor onset between the two host geno-
types (Figure 3). Wild type and Notch4−/− mice received
intravenous injections of Cy3-lectin to highlight vessel per-
fusion, and tumor sections were immunostained with anti-
bodies against CD31 to highlight overall tumor vasculature
(Figure 4a). We found that the number of perfused vessel
segments in tumors of Notch4−/− hosts decreased signifi-
cantly compared to those of wild type hosts (Figure 4b).
Surprisingly, we did not detect any statistically significant
differences in the total number of vessel segments and
branch points between tumors developed in wild type and
Notch4−/− hosts (Figure 4c and d). To confirm that vessel
density is similar between tumors developed in wild type
and Notch4−/− hosts, we quantified vessel segments at
14 days after transplantation when tumor incidence is still
significantly reduced (Figure 3). At this time point, we also
did not detect any significant differences in vessel density
between the two groups (Figure 4e and f). These findingssuggest that host Notch4 is required for adequate ini-
tial tumor vessel perfusion, but dispensable for vessel
sprouting.
Next we examined whether host Notch4 was required
for tumor progression after tumor onset. Tumor-bearing
wild type and Notch4−/− mice were dissected three
weeks after transplantation, when tumor incidence is
comparable between the two host genotypes. At this
stage, tumor mass did not differ significantly between
wild type and Notch4−/− hosts (Figure 5a) and the vascu-
lar architecture was also similar (Figure 5b). These re-
sults suggest tumors can eventually grow in Notch4−/−
hosts.
Discussion
In this study we demonstrate that Notch4 expression is
upregulated in the vasculature of mammary tumors. Fur-
thermore, our results suggest that host Notch4 plays a
role in the early emergence of MMTV-PyMT breast tu-
mors following transplantation. We also found that host
Notch4 is required for initial tumor vascular perfusion,
but not vessel sprouting. To our knowledge, this is the
first report demonstrating the functional relevance of host
Notch4 upregulation in tumorigenesis and tumor vessel
perfusion. Our findings shed light on the role of Notch4,
independent of other Notch receptors, in tumor-host
interactions.
Our results show increased levels of Notch4 in the
blood vessels of mouse and human breast tumor tissues.
Expression of Notch receptors and ligands has been de-
scribed in a wide variety of different tumor types, such
as colorectal, prostate, liver, pancreatic and breast cancer
[23,24] and a role for Notch4 in regulating breast cancer
Figure 4 Vascular perfusion is compromised in tumors developed in Notch4−/− hosts whereas vessel density is unaffected. (a) CD31
immunostaining (green) and lectin-perfused (red) blood vessel patterns in orthotopic MMTV-PyMT tumors are similar in wild type (i) and
Notch4−/− (ii) hosts. (b) Vessel perfusion in MMTV-PyMT tumors is decreased in Notch4−/− hosts compared to wild type hosts 9 days after
orthotopic transplantation. (c and d) Vessel density, either measured as number of vessel segments (c) or as number of branch points (d) in
MMTV-PyMT tumors is similar in wild type and Notch4−/− hosts 9 days after orthotopic transplantation. (e) CD31 staining in tumors developed
in wild type (i) and Notch4−/− (ii) hosts 2 weeks after transplantation. (f) Vessel density in MMTV-PyMT tumors is similar in wild type and
Notch4−/− hosts 2 weeks after orthotopic transplantation. Bars represent average values and error bars represent s.e.m.
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Figure 5 Tumor mass and vascular architecture are similar in tumors developed in wild type and Notch4−/− hosts at later stages.
(a) Tumor mass of MMTV-PyMT tumors at 3 weeks after orthotopic transplantation. Bars represent average values and error bars represent s.e.m.
(b) CD31 staining highlighting tumor vascular architecture 3 weeks after orthotopic transplantation.
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reported that the levels of Notch receptors (1, 2, and 4)
and ligands (Jagged 1, 2, Dll1, and 4) are increased in
human breast cancer compared to normal breast tissue
[26]. Recently, a study by Speiser and collaborators
showed increased Notch1 and Notch4 levels in tumor epi-
thelial cells and vascular endothelial cells in triple-negative
breast cancer samples [27], therefore highlighting the rele-
vance of Notch4 expression in the vasculature. However,
in our studies, we did not observe Notch4 staining in ei-
ther human (Figure 1c) or murine tumor cells (Figure 1a,
ix, xii and 1b, iii), but rather observed Notch4 up-
regulation in the tumor vasculature. We used a well-
characterized Notch4-specific antibody [28] and verified its
specificity using Notch4 knockout tissues (Additional file 1:
Figure S1). Our study demonstrates Notch4 upregulation in
the vasculature of both mouse models of mammary adeno-
carcinoma and human breast cancer. It is possible that
different types and grades of breast carcinoma present
different Notch4 expression levels and distribution.
However, in our study, our mouse model provides evi-
dence that host, likely vascular, Notch4 plays a role in
breast cancer development. Consistent with our findingthat Notch4 is expressed in the tumor vasculature, the
Notch ligand Dll4 is detected in the vessels of infiltrat-
ing human breast adenocarcinoma samples [29], making
it a possible ligand for Notch4 in tumor vasculature.
Orthotopic transplantation of mammary tumor cells is
a well-established model for in vivo studies of breast
tumorigenesis, and we chose this approach because it
allowed us to study host Notch4-mediated effects on
tumorigenesis independent of Notch4 activity in the
tumor cell compartment. We demonstrate a contribu-
tion of the tumor microenvironment, namely the host
Notch4, to tumorigenesis. We also pinpoint that the
tumorigenic defect lies at the tumor onset following
transplantation. It is well documented that the growth of
solid tumors depends on the development of new vascu-
lature [30]. Inhibition of members of the Notch signaling
pathway leads to an increase in “non-productive” angio-
genesis, characterized by a reduction in vessel perfusion
despite an increase in vessel sprouting [9-11,31]. We
thus examined vascular perfusion in tumors grown in
Notch4−/− hosts. Since both the mammary gland and its
vasculature appear normal in Notch4−/− mice, we reasoned
that any vascular defects in tumors from Notch4−/− hosts
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genesis, and not as a result of preexisting vascular defects.
We observed that vessel perfusion was reduced in tumors
grown in Notch4−/− vs. wild type hosts. This observation is
consistent with many reports of Notch pathway inhibition
leading to reduced perfusion [9-11,31].
Although poor tumor vessel perfusion correlated sig-
nificantly with delayed tumor onset at early time points
after transplantation, our results alone do not provide
causal proof that reduced vessel perfusion leads to de-
layed tumor onset in Notch4−/− mice. Given the complex
dynamics in tumor-host interaction and tumor micro-
environment, we cannot rule out the possibility that vas-
cular Notch4 (and other Notch pathway proteins) may
regulate tumor onset by mechanisms that are independ-
ent of vessel perfusion. It is also possible that differences
in transplantation-associated immune responses contrib-
ute to the delayed tumor onset in Notch4−/− hosts. Both
tumor-associated fibroblasts and tumor-infiltrating leuko-
cytes have been shown to play an important role in tumor
onset and growth [32]. Notch4 expression has been
detected in immune cells of myeloid lineage [21]. Al-
though we detected Notch4 overexpression predominantly
in the tumor vasculature, we cannot rule out the possibil-
ity that host myeloid cells may contribute to the difference
in tumor onset between the two host genotypes.
Host Notch4 deficiency delays tumor onset and de-
creases initial perfusion, however, the growth of
established tumors can ultimately progress in the ab-
sence of host Notch4. This result suggests that host
Notch4 plays a unique role in the initiation of tumor
onset after transplantation.
Surprisingly, our results indicate that Notch4 is dis-
pensable for vessel sprouting in the tumor. Sprouting
angiogenesis is a hallmark of tumor neovascularization,
and Dll4/Notch1 signaling functions to inhibit vessel
sprouting [8]. Moreover, given that Notch1 appears to be
the primary Notch receptor responsible for developmental
angiogenesis [3], together with the results obtained using
specific anti-Notch1 antibodies in tumors [11], Notch1
seems to be the predominant mediator of Notch signaling
in tumor angiogenesis. It is therefore likely that the in-
creased vascular network observed when inhibiting
pan-Notch signaling or Notch ligands is mainly due to
the inhibition of Notch1. Alternatively, it is possible that a
subtle defect in vessel sprouting exists in the Notch4−/−
tumor vasculature, but current methodologies are not
sensitive enough to detect such subtle phenotype.
Conclusion
Our finding that the lack of Notch4 does not increase
vascular density, but does affect tumorigenesis and ves-
sel perfusion suggests a unique mechanism distinct from
that mediated by Notch1. Our work uncovers a novelrole of Notch4 in the early establishment of vessel perfu-
sion; whether this is a mechanism unique to tumor ves-
sel angiogenesis or whether it is present also during
development or in other postnatal angiogenic settings
remains to be determined.
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